Baird analyst David Rodgers raised the firm’s price target on Cencora to $227 from $223 and keeps an Outperform rating on the shares. The firm said they reported 3Q results well above expectations, largely driven by DecisionDx-SCC Medicare revenue not included in guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COR: